臨床試験番号 NCT00769704 研究名 "Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma" - ClinicalTrials.gov
臨床試験番号 NCT01161498 研究名 "Study of Safety and Efficacy of OncoVEXGM-CSF With Cisplatin for Treatment of Locally Advanced Head and Neck Cancer" - ClinicalTrials.gov
臨床試験番号 NCT01387555 研究名 "A Phase 2b Study of Vaccinia Virus to Treat Advanced Liver Cancer (TRAVERSE)" - ClinicalTrials.gov
臨床試験番号 NCT00625456 研究名 "Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors" - ClinicalTrials.gov
臨床試験番号 NCT01048892 研究名 "Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features" - ClinicalTrials.gov, October 2012
臨床試験番号 NCT01017601 研究名 "Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer" - ClinicalTrials.gov
臨床試験番号 NCT00794131 研究名 "Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors" - ClinicalTrials.gov
臨床試験番号 NCT01766739 研究名 "Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma" - ClinicalTrials.gov
臨床試験番号 NCT01443260 研究名 "A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis" - ClinicalTrials.gov
臨床試験番号 NCT01584284 研究名 "Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer" - ClinicalTrials.gov
臨床試験番号 NCT00832559 研究名 "A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients" - ClinicalTrials.gov
臨床試験番号 NCT01227551 研究名 "A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma" - ClinicalTrials.gov
Ferguson, Mark S.; Lemoine, Nicholas R.; Wang, Yaohe (2012). “Systemic Delivery of Oncolytic Viruses: Hopes and Hurdles”. Advances in Virology2012: 1. doi:10.1155/2012/805629.
Lichty, Brian D.; Breitbach, Caroline J.; Stojdl, David F.; Bell, John C. (2014). “Going viral with cancer immunotherapy”. Nat Rev Cancer14 (8): 559–67. doi:10.1038/nrc3770. PMID24990523.
g. Donnelly, O.; Errington-Mais, F.; Prestwich, R.; Harrington, K.; Pandha, H.; Vile, R.; Melcher, A. (2012). “Recent Clinical Experience with Oncolytic Viruses”. Current Pharmaceutical Biotechnology13 (9): 1834–41. doi:10.2174/138920112800958904. PMID21740364.
Rudin, Charles M.; John T. Poirier; Neil N. Senzer; Joseph Stephenson; David Loesch; Kevin D. Burroughs author7=P. Seshidhar Reddy (2011-02-15). “Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.”. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research17 (4): 888–895. doi:10.1158/1078-0432.CCR-10-1706. ISSN1078-0432. PMID21304001.
Bourke, M.G.; Salwa, S.; Harrington, K.J.; Kucharczyk, M.J.; Forde, P.F.; De Kruijf, M.; Soden, D.; Tangney, M. et al. (2011). “The emerging role of viruses in the treatment of solid tumours”. Cancer Treatment Reviews37 (8): 618–32. doi:10.1016/j.ctrv.2010.12.003. PMID21232872.
Kuruppu, Darshini; Tanabe, Kenneth K. (2005). “Viral oncolysis by herpes simplex virus and other viruses”. Cancer Biology & Therapy4 (5): 524–31. doi:10.4161/cbt.4.5.1820. PMID15917655.
Kelly, Elizabeth; Russell, Stephen J (2007). “History of Oncolytic Viruses: Genesis to Genetic Engineering”. Molecular Therapy15 (4): 651–9. doi:10.1038/sj.mt.6300108. PMID17299401.
MacLean, A. R.; Ul-Fareed, M.; Robertson, L.; Harland, J.; Brown, S. M. (1991). “Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence”. Journal of General Virology72 (3): 631. doi:10.1099/0022-1317-72-3-631.
Brown, S. M.; Harland, J.; MacLean, A. R.; Podlech, J.; Clements, J. B. (1994). “Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2”. Journal of General Virology75 (9): 2367. doi:10.1099/0022-1317-75-9-2367.
Randazzo, Bruce P; Bhat, Mulki G; Kesari, Santosh; Fraser, Nigel W; Brown, S Moira (1997). “Treatment of Experimental Subcutaneous Human Melanoma with a Replication-Restricted Herpes Simplex Virus Mutant”. Journal of Investigative Dermatology108 (6): 933–7. doi:10.1111/1523-1747.ep12295238. PMID9182825.
Rampling, R; Cruickshank, G; Papanastassiou, V; Nicoll, J; Hadley, D; Brennan, D; Petty, R; MacLean, A et al. (2000). “Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma”. Gene Therapy7 (10): 859–66. doi:10.1038/sj.gt.3301184. PMID10845724.
Papanastassiou, V; Rampling, R; Fraser, M; Petty, R; Hadley, D; Nicoll, J; Harland, J; Mabbs, R et al. (2002). “The potential for efficacy of the modified (ICP 34.5−) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: A proof of principle study”. Gene Therapy9 (6): 398–406. doi:10.1038/sj.gt.3301664. PMID11960316.
Harrow, S; Papanastassiou, V; Harland, J; Mabbs, R; Petty, R; Fraser, M; Hadley, D; Patterson, J et al. (2004). “HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety data and long-term survival”. Gene Therapy11 (22): 1648–58. doi:10.1038/sj.gt.3302289. PMID15334111.
MacKie, Rona M; Stewart, Barry; Brown, S Moira (2001). “Intralesional injection of herpes simplex virus 1716 in metastatic melanoma”. The Lancet357 (9255): 525–6. doi:10.1016/S0140-6736(00)04048-4. PMID11229673.
Mace, Alastair T. M.; Ganly, Ian; Soutar, David S.; Brown, S. Moira (2008). “Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma”. Head & Neck30 (8): 1045–51. doi:10.1002/hed.20840. PMID18615711.
Conner, J; Braidwood, L; Brown, S M (2008). “A strategy for systemic delivery of the oncolytic herpes virus HSV1716: Redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein”. Gene Therapy15 (24): 1579–92. doi:10.1038/gt.2008.121. PMID18701918.
Sorensen, A.; Mairs, R. J.; Braidwood, L.; Joyce, C.; Conner, J.; Pimlott, S.; Brown, M.; Boyd, M. (2012). “In Vivo Evaluation of a Cancer Therapy Strategy Combining HSV1716-Mediated Oncolysis with Gene Transfer and Targeted Radiotherapy”. Journal of Nuclear Medicine53 (4): 647–54. doi:10.2967/jnumed.111.090886. PMID22414636.
Frew, Sarah E; Sammut, Stephen M; Shore, Alysha F; Ramjist, Joshua K; Al-Bader, Sara; Rezaie, Rahim; Daar, Abdallah S; Singer, Peter A (2008). “Chinese health biotech and the billion-patient market”. Nature Biotechnology26 (1): 37–53. doi:10.1038/nbt0108-37. PMID18183014.
Garber, K. (2006). “China Approves World's First Oncolytic Virus Therapy for Cancer Treatment”. JNCI Journal of the National Cancer Institute98 (5): 298–300. doi:10.1093/jnci/djj111. PMID16507823.
Cheema, T. A.; Wakimoto, H.; Fecci, P. E.; Ning, J.; Kuroda, T.; Jeyaretna, D. S.; Martuza, R. L.; Rabkin, S. D. (2013). “Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model”. Proceedings of the National Academy of Sciences110 (29): 12006. doi:10.1073/pnas.1307935110.
Bell, John; Roy, Dominic (2013). “Cell carriers for oncolytic viruses: Current challenges and future directions”. Oncolytic Virotherapy: 47. doi:10.2147/OV.S36623.
Bell, John C.; Lichty, David F.; Knowles, Brian; Marius, Shane; Atkins, Ricardo; Sonenberg, Harold; Bell, Nahum (2000). “Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus”. Nature Medicine6 (7): 821–5. doi:10.1038/77558. PMID10888934.
Stojdl, David F; Lichty, Brian D; Tenoever, Benjamin R; Paterson, Jennifer M; Power, Anthony T; Knowles, Shane; Marius, Ricardo; Reynard, Jennifer et al. (2003). “VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents”. Cancer Cell4 (4): 263–75. doi:10.1016/S1535-6108(03)00241-1. PMID14585354.
Ahmed, M; Cramer, S; Lyles, D (2004). “Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses”. Virology330 (1): 34–49. doi:10.1016/j.virol.2004.08.039. PMID15527832.
Ebert, Oliver; Harbaran, Sonal; Shinozaki, Katsunori; Woo, Savio L C (2004). “Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice”. Cancer Gene Therapy12 (4): 350–8. doi:10.1038/sj.cgt.7700794. PMID15565179.
Goetz, Christian; Gromeier, Matthias (2010). “Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme”. Cytokine & Growth Factor Reviews21 (2–3): 197. doi:10.1016/j.cytogfr.2010.02.005.
Thirukkumaran, Chandini; Morris, Don G. (2009). Oncolytic Viral Therapy Using Reovirus. “Gene Therapy of Cancer”. Methods in molecular biology. Methods in Molecular Biology 542: 607–34. doi:10.1007/978-1-59745-561-9_31. ISBN978-1-934115-85-5. PMID19565924.
Gentry, Glenn A. (1992). “Viral thymidine kinases and their relatives”. Pharmacology & Therapeutics54 (3): 319. doi:10.1016/0163-7258(92)90006-L.
Davydova, J.; Le, LP; Gavrikova, T; Wang, M; Krasnykh, V; Yamamoto, M (2004). “Infectivity-Enhanced Cyclooxygenase-2-Based Conditionally Replicative Adenoviruses for Esophageal Adenocarcinoma Treatment”. Cancer Research64 (12): 4319–27. doi:10.1158/0008-5472.CAN-04-0064. PMID15205347.
Poirier, J. T.; Reddy, P. S.; Idamakanti, N.; Li, S. S.; Stump, K. L.; Burroughs, K. D.; Hallenbeck, P. L.; Rudin, C. M. (2012). “Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001”. Journal of General Virology93 (Pt 12): 2606–13. doi:10.1099/vir.0.046011-0. PMID22971818.
Yu, Yong A; Shabahang, Shahrokh; Timiryasova, Tatyana M; Zhang, Qian; Beltz, Richard; Gentschev, Ivaylo; Goebel, Werner; Szalay, Aladar A (2004). “Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins”. Nature Biotechnology22 (3): 313–20. doi:10.1038/nbt937. PMID14990953.
Duarte, Sónia; Carle, Georges; Faneca, Henrique; De Lima, Maria C. Pedroso de; Pierrefite-Carle, Valérie (2012). “Suicide gene therapy in cancer: Where do we stand now?”. Cancer Letters324 (2): 160–70. doi:10.1016/j.canlet.2012.05.023. PMID22634584.
Conner, J; Braidwood, L (2012). “Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy”. Cancer Gene Therapy19 (7): 499–507. doi:10.1038/cgt.2012.24. PMID22595793.
Grünwald, G K; Klutz, K; Willhauck, M J; Schwenk, N; Senekowitsch-Schmidtke, R; Schwaiger, M; Zach, C; Göke, B et al. (2012). “Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus”. Gene Therapy20 (6): 625–33. doi:10.1038/gt.2012.79. PMID23038026.
Schmidt, C. (2013). “Awaiting a Moment of Truth for Oncolytic Viruses”. JNCI Journal of the National Cancer Institute105 (10): 675. doi:10.1093/jnci/djt111.
Lolkema, M. P.; Arkenau, H.-T.; Harrington, K.; Roxburgh, P.; Morrison, R.; Roulstone, V.; Twigger, K.; Coffey, M. et al. (2010). “A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer”. Clinical Cancer Research17 (3): 581–8. doi:10.1158/1078-0432.CCR-10-2159. PMID21106728.
Magge, D; Guo, Z S; O'Malley, M E; Francis, L; Ravindranathan, R; Bartlett, D L (2013). “Inhibitors of C5 complement enhance vaccinia virus oncolysis”. Cancer Gene Therapy20 (6): 342–50. doi:10.1038/cgt.2013.26. PMID23661042.
Heo, Jeong; Reid, Tony; Ruo, Leyo; Breitbach, Caroline J; Rose, Steven; Bloomston, Mark; Cho, Mong; Lim, Ho Yeong et al. (2013). “Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer”. Nature Medicine19 (3): 329–36. doi:10.1038/nm.3089. PMID23396206.
Muthana, M.; Rodrigues, S.; Chen, Y.-Y.; Welford, A.; Hughes, R.; Tazzyman, S.; Essand, M.; Morrow, F. et al. (2012). “Macrophage Delivery of an Oncolytic Virus Abolishes Tumor Regrowth and Metastasis after Chemotherapy or Irradiation”. Cancer Research73 (2): 490–5. doi:10.1158/0008-5472.CAN-12-3056. PMID23172310.
w. Tong, Alex; Senzer, Neil; Cerullo, Vincenzo; Templeton, Nancy; Hemminki, Akseli; Nemunaitis, John (2012). “Oncolytic Viruses for Induction of Anti-Tumor Immunity”. Current Pharmaceutical Biotechnology13 (9): 1750–60. doi:10.2174/138920112800958913. PMID21740355.
Mastrangelo, Michael J; Lattime, Edmund C (2002). “Virotherapy clinical trials for regional disease: In situ immune modulation using recombinant poxvirus vectors”. Cancer Gene Therapy9 (12): 1013–21. doi:10.1038/sj.cgt.7700538. PMID12522440.
Mace, >A.T.M.; Harrow, S.J.; Ganly, I.; Brown, S.M. (2007). “Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma”. Acta Oto-laryngologica127 (8): 880–7. doi:10.1080/00016480601075381. PMID17763002.
Toyoizumi, Takane; Mick, Rosemarie; Abbas, Abbas E.; Kang, Eugene H.; Kaiser, Larry R.; Molnar-Kimber, Katherine L. (1999). “Combined Therapy with Chemotherapeutic Agents and Herpes Simplex Virus Type 1 ICP34.5 Mutant (HSV-1716) in Human Non-Small Cell Lung Cancer”. Human Gene Therapy10 (18): 3013–29. doi:10.1089/10430349950016410. PMID10609661.
Khuri, Fadlo R.; Nemunaitis, John; Ganly, Ian; Arseneau, James; Tannock, Ian F.; Romel, Larry; Gore, Martin; Ironside, Janet et al. (2000). “A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer”. Nature Medicine6 (8): 879–85. doi:10.1038/78638. PMID10932224.
Schmidt, Charlie (2011). “Amgen spikes interest in live virus vaccines for hard-to-treat cancers”. Nature Biotechnology29 (4): 295–6. doi:10.1038/nbt0411-295. PMID21478830.
Sheridan C (2015-06-09). “First oncolytic virus edges towards approval in surprise vote.”. Nature Biotechnology33: 569–70. doi:10.1038/nbt0615-569. PMID26057953.
j. Breitbach, Caroline; Thorne, Steve; Bell, John; Kirn, David (2012). “Targeted and Armed Oncolytic Poxviruses for Cancer: The Lead Example of JX-594”. Current Pharmaceutical Biotechnology13 (9): 1768–72. doi:10.2174/138920112800958922. PMID21740365.
Lichty, Brian D.; Breitbach, Caroline J.; Stojdl, David F.; Bell, John C. (2014). “Going viral with cancer immunotherapy”. Nat Rev Cancer14 (8): 559–67. doi:10.1038/nrc3770. PMID24990523.
g. Donnelly, O.; Errington-Mais, F.; Prestwich, R.; Harrington, K.; Pandha, H.; Vile, R.; Melcher, A. (2012). “Recent Clinical Experience with Oncolytic Viruses”. Current Pharmaceutical Biotechnology13 (9): 1834–41. doi:10.2174/138920112800958904. PMID21740364.
Roberts, MS; Lorence, RM; Groene, WS; Bamat, MK (2006). “Naturally oncolytic viruses”. Current opinion in molecular therapeutics8 (4): 314–21. PMID16955694.
Rudin, Charles M.; John T. Poirier; Neil N. Senzer; Joseph Stephenson; David Loesch; Kevin D. Burroughs author7=P. Seshidhar Reddy (2011-02-15). “Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.”. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research17 (4): 888–895. doi:10.1158/1078-0432.CCR-10-1706. ISSN1078-0432. PMID21304001.
Bourke, M.G.; Salwa, S.; Harrington, K.J.; Kucharczyk, M.J.; Forde, P.F.; De Kruijf, M.; Soden, D.; Tangney, M. et al. (2011). “The emerging role of viruses in the treatment of solid tumours”. Cancer Treatment Reviews37 (8): 618–32. doi:10.1016/j.ctrv.2010.12.003. PMID21232872.
Kuruppu, Darshini; Tanabe, Kenneth K. (2005). “Viral oncolysis by herpes simplex virus and other viruses”. Cancer Biology & Therapy4 (5): 524–31. doi:10.4161/cbt.4.5.1820. PMID15917655.
Voroshilova, MK (1989). “Potential use of nonpathogenic enteroviruses for control of human disease”. Progress in medical virology36: 191–202. PMID2555836.
Randazzo, Bruce P; Bhat, Mulki G; Kesari, Santosh; Fraser, Nigel W; Brown, S Moira (1997). “Treatment of Experimental Subcutaneous Human Melanoma with a Replication-Restricted Herpes Simplex Virus Mutant”. Journal of Investigative Dermatology108 (6): 933–7. doi:10.1111/1523-1747.ep12295238. PMID9182825.
Rampling, R; Cruickshank, G; Papanastassiou, V; Nicoll, J; Hadley, D; Brennan, D; Petty, R; MacLean, A et al. (2000). “Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma”. Gene Therapy7 (10): 859–66. doi:10.1038/sj.gt.3301184. PMID10845724.
Papanastassiou, V; Rampling, R; Fraser, M; Petty, R; Hadley, D; Nicoll, J; Harland, J; Mabbs, R et al. (2002). “The potential for efficacy of the modified (ICP 34.5−) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: A proof of principle study”. Gene Therapy9 (6): 398–406. doi:10.1038/sj.gt.3301664. PMID11960316.
Harrow, S; Papanastassiou, V; Harland, J; Mabbs, R; Petty, R; Fraser, M; Hadley, D; Patterson, J et al. (2004). “HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety data and long-term survival”. Gene Therapy11 (22): 1648–58. doi:10.1038/sj.gt.3302289. PMID15334111.
MacKie, Rona M; Stewart, Barry; Brown, S Moira (2001). “Intralesional injection of herpes simplex virus 1716 in metastatic melanoma”. The Lancet357 (9255): 525–6. doi:10.1016/S0140-6736(00)04048-4. PMID11229673.
Mace, Alastair T. M.; Ganly, Ian; Soutar, David S.; Brown, S. Moira (2008). “Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma”. Head & Neck30 (8): 1045–51. doi:10.1002/hed.20840. PMID18615711.
Conner, J; Braidwood, L; Brown, S M (2008). “A strategy for systemic delivery of the oncolytic herpes virus HSV1716: Redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein”. Gene Therapy15 (24): 1579–92. doi:10.1038/gt.2008.121. PMID18701918.
Braidwood, L; Dunn, PD; Hardy, S; Evans, TR; Brown, SM (2009). “Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy”. Anticancer research29 (6): 2159–66. PMID19528476.
Sorensen, A.; Mairs, R. J.; Braidwood, L.; Joyce, C.; Conner, J.; Pimlott, S.; Brown, M.; Boyd, M. (2012). “In Vivo Evaluation of a Cancer Therapy Strategy Combining HSV1716-Mediated Oncolysis with Gene Transfer and Targeted Radiotherapy”. Journal of Nuclear Medicine53 (4): 647–54. doi:10.2967/jnumed.111.090886. PMID22414636.
Frew, Sarah E; Sammut, Stephen M; Shore, Alysha F; Ramjist, Joshua K; Al-Bader, Sara; Rezaie, Rahim; Daar, Abdallah S; Singer, Peter A (2008). “Chinese health biotech and the billion-patient market”. Nature Biotechnology26 (1): 37–53. doi:10.1038/nbt0108-37. PMID18183014.
Garber, K. (2006). “China Approves World's First Oncolytic Virus Therapy for Cancer Treatment”. JNCI Journal of the National Cancer Institute98 (5): 298–300. doi:10.1093/jnci/djj111. PMID16507823.
Bell, John C.; Lichty, David F.; Knowles, Brian; Marius, Shane; Atkins, Ricardo; Sonenberg, Harold; Bell, Nahum (2000). “Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus”. Nature Medicine6 (7): 821–5. doi:10.1038/77558. PMID10888934.
Stojdl, David F; Lichty, Brian D; Tenoever, Benjamin R; Paterson, Jennifer M; Power, Anthony T; Knowles, Shane; Marius, Ricardo; Reynard, Jennifer et al. (2003). “VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents”. Cancer Cell4 (4): 263–75. doi:10.1016/S1535-6108(03)00241-1. PMID14585354.
Ahmed, M; Cramer, S; Lyles, D (2004). “Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses”. Virology330 (1): 34–49. doi:10.1016/j.virol.2004.08.039. PMID15527832.
Ebert, Oliver; Harbaran, Sonal; Shinozaki, Katsunori; Woo, Savio L C (2004). “Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice”. Cancer Gene Therapy12 (4): 350–8. doi:10.1038/sj.cgt.7700794. PMID15565179.
Lal, R; Harris, D; Postel-Vinay, S; De Bono, J (2009). “Reovirus: Rationale and clinical trial update”. Current opinion in molecular therapeutics11 (5): 532–9. PMID19806501.
Thirukkumaran, Chandini; Morris, Don G. (2009). Oncolytic Viral Therapy Using Reovirus. “Gene Therapy of Cancer”. Methods in molecular biology. Methods in Molecular Biology 542: 607–34. doi:10.1007/978-1-59745-561-9_31. ISBN978-1-934115-85-5. PMID19565924.
Davydova, J.; Le, LP; Gavrikova, T; Wang, M; Krasnykh, V; Yamamoto, M (2004). “Infectivity-Enhanced Cyclooxygenase-2-Based Conditionally Replicative Adenoviruses for Esophageal Adenocarcinoma Treatment”. Cancer Research64 (12): 4319–27. doi:10.1158/0008-5472.CAN-04-0064. PMID15205347.
Poirier, J. T.; Reddy, P. S.; Idamakanti, N.; Li, S. S.; Stump, K. L.; Burroughs, K. D.; Hallenbeck, P. L.; Rudin, C. M. (2012). “Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001”. Journal of General Virology93 (Pt 12): 2606–13. doi:10.1099/vir.0.046011-0. PMID22971818.
Yu, Yong A; Shabahang, Shahrokh; Timiryasova, Tatyana M; Zhang, Qian; Beltz, Richard; Gentschev, Ivaylo; Goebel, Werner; Szalay, Aladar A (2004). “Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins”. Nature Biotechnology22 (3): 313–20. doi:10.1038/nbt937. PMID14990953.
Freeman, SM; Whartenby, KA; Freeman, JL; Abboud, CN; Marrogi, AJ (1996). “In situ use of suicide genes for cancer therapy”. Seminars in oncology23 (1): 31–45. PMID8607030.
Duarte, Sónia; Carle, Georges; Faneca, Henrique; De Lima, Maria C. Pedroso de; Pierrefite-Carle, Valérie (2012). “Suicide gene therapy in cancer: Where do we stand now?”. Cancer Letters324 (2): 160–70. doi:10.1016/j.canlet.2012.05.023. PMID22634584.
Conner, J; Braidwood, L (2012). “Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy”. Cancer Gene Therapy19 (7): 499–507. doi:10.1038/cgt.2012.24. PMID22595793.
Grünwald, G K; Klutz, K; Willhauck, M J; Schwenk, N; Senekowitsch-Schmidtke, R; Schwaiger, M; Zach, C; Göke, B et al. (2012). “Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus”. Gene Therapy20 (6): 625–33. doi:10.1038/gt.2012.79. PMID23038026.
Lolkema, M. P.; Arkenau, H.-T.; Harrington, K.; Roxburgh, P.; Morrison, R.; Roulstone, V.; Twigger, K.; Coffey, M. et al. (2010). “A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer”. Clinical Cancer Research17 (3): 581–8. doi:10.1158/1078-0432.CCR-10-2159. PMID21106728.
Magge, D; Guo, Z S; O'Malley, M E; Francis, L; Ravindranathan, R; Bartlett, D L (2013). “Inhibitors of C5 complement enhance vaccinia virus oncolysis”. Cancer Gene Therapy20 (6): 342–50. doi:10.1038/cgt.2013.26. PMID23661042.
Heo, Jeong; Reid, Tony; Ruo, Leyo; Breitbach, Caroline J; Rose, Steven; Bloomston, Mark; Cho, Mong; Lim, Ho Yeong et al. (2013). “Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer”. Nature Medicine19 (3): 329–36. doi:10.1038/nm.3089. PMID23396206.
Muthana, M.; Rodrigues, S.; Chen, Y.-Y.; Welford, A.; Hughes, R.; Tazzyman, S.; Essand, M.; Morrow, F. et al. (2012). “Macrophage Delivery of an Oncolytic Virus Abolishes Tumor Regrowth and Metastasis after Chemotherapy or Irradiation”. Cancer Research73 (2): 490–5. doi:10.1158/0008-5472.CAN-12-3056. PMID23172310.
w. Tong, Alex; Senzer, Neil; Cerullo, Vincenzo; Templeton, Nancy; Hemminki, Akseli; Nemunaitis, John (2012). “Oncolytic Viruses for Induction of Anti-Tumor Immunity”. Current Pharmaceutical Biotechnology13 (9): 1750–60. doi:10.2174/138920112800958913. PMID21740355.
Mastrangelo, Michael J; Lattime, Edmund C (2002). “Virotherapy clinical trials for regional disease: In situ immune modulation using recombinant poxvirus vectors”. Cancer Gene Therapy9 (12): 1013–21. doi:10.1038/sj.cgt.7700538. PMID12522440.
Mace, >A.T.M.; Harrow, S.J.; Ganly, I.; Brown, S.M. (2007). “Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma”. Acta Oto-laryngologica127 (8): 880–7. doi:10.1080/00016480601075381. PMID17763002.
Toyoizumi, Takane; Mick, Rosemarie; Abbas, Abbas E.; Kang, Eugene H.; Kaiser, Larry R.; Molnar-Kimber, Katherine L. (1999). “Combined Therapy with Chemotherapeutic Agents and Herpes Simplex Virus Type 1 ICP34.5 Mutant (HSV-1716) in Human Non-Small Cell Lung Cancer”. Human Gene Therapy10 (18): 3013–29. doi:10.1089/10430349950016410. PMID10609661.
Khuri, Fadlo R.; Nemunaitis, John; Ganly, Ian; Arseneau, James; Tannock, Ian F.; Romel, Larry; Gore, Martin; Ironside, Janet et al. (2000). “A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer”. Nature Medicine6 (8): 879–85. doi:10.1038/78638. PMID10932224.
Schmidt, Charlie (2011). “Amgen spikes interest in live virus vaccines for hard-to-treat cancers”. Nature Biotechnology29 (4): 295–6. doi:10.1038/nbt0411-295. PMID21478830.
Sheridan C (2015-06-09). “First oncolytic virus edges towards approval in surprise vote.”. Nature Biotechnology33: 569–70. doi:10.1038/nbt0615-569. PMID26057953.
j. Breitbach, Caroline; Thorne, Steve; Bell, John; Kirn, David (2012). “Targeted and Armed Oncolytic Poxviruses for Cancer: The Lead Example of JX-594”. Current Pharmaceutical Biotechnology13 (9): 1768–72. doi:10.2174/138920112800958922. PMID21740365.
臨床試験番号 NCT00769704 研究名 "Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma" - ClinicalTrials.gov
臨床試験番号 NCT01161498 研究名 "Study of Safety and Efficacy of OncoVEXGM-CSF With Cisplatin for Treatment of Locally Advanced Head and Neck Cancer" - ClinicalTrials.gov
臨床試験番号 NCT01387555 研究名 "A Phase 2b Study of Vaccinia Virus to Treat Advanced Liver Cancer (TRAVERSE)" - ClinicalTrials.gov
臨床試験番号 NCT00625456 研究名 "Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors" - ClinicalTrials.gov
臨床試験番号 NCT01048892 研究名 "Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features" - ClinicalTrials.gov, October 2012
臨床試験番号 NCT01017601 研究名 "Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer" - ClinicalTrials.gov
臨床試験番号 NCT00794131 研究名 "Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors" - ClinicalTrials.gov
臨床試験番号 NCT01766739 研究名 "Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma" - ClinicalTrials.gov
臨床試験番号 NCT01443260 研究名 "A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis" - ClinicalTrials.gov
臨床試験番号 NCT01584284 研究名 "Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer" - ClinicalTrials.gov
臨床試験番号 NCT00832559 研究名 "A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients" - ClinicalTrials.gov
臨床試験番号 NCT01227551 研究名 "A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma" - ClinicalTrials.gov
worldcat.org
search.worldcat.org
Rudin, Charles M.; John T. Poirier; Neil N. Senzer; Joseph Stephenson; David Loesch; Kevin D. Burroughs author7=P. Seshidhar Reddy (2011-02-15). “Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.”. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research17 (4): 888–895. doi:10.1158/1078-0432.CCR-10-1706. ISSN1078-0432. PMID21304001.